Rossari Biotech Ltd (ROSSARI) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Rossari Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Transcript of Q2 & H1 FY27 for the Earnings Conference Call held on October 19, 2026
Transcript · 23 Oct 2026, 1:02 am
Audio recording of Earnings Conference Call for Q2 & H1 FY 27.
Audio / Video · 20 Oct 2026, 1:23 am
Rossari Biotech Releases Audio Recording for Q2 & H1 FY27 Earnings Call Rossari Biotech Limited announced that the audio recording of its Q2 & H1 FY27 earnings conference call, conducted with analysts and investors on 19th Oct'26, is now accessible on the company's official website under the 'Investor Call' section.
Press Release for Q2 FY27 Results
Press Release · 19 Oct 2026, 6:18 am
Rossari Biotech Posts Record Q2 FY27 Financial Results with Strategic Global Expansion Rossari Biotech reported record quarterly consolidated revenue of Rs. 697.6 crores, up 19.0% YoY, and highest-ever EBITDA of Rs. 87.0 crores, up 20.9% YoY with margins at 12.5% (+20 bps). Q2 PAT stood at Rs. 38.9 crores, subdued by higher depreciation. Export sales rose 33.8% YoY to Rs. 216.4 crores. As of Sep'26, net debt fell to Rs. 221 crores from Rs. 281 crores in Mar'26. Additionally, the board approved land leasing for a greenfield manufacturing plant in Saudi Arabia.
Intimation of Q2 & H1 FY27- Earnings Presentation
Investor Presentation · 19 Oct 2026, 6:07 am
Rossari Biotech Posts 19% Revenue Growth in Q2FY27 Alongside Saudi Expansion Rossari Biotech reported Q2FY27 consolidated revenue of Rs. 697.6 crores, up 19.0% YoY, while EBITDA rose 20.9% YoY to Rs. 87.0 crores with margins at 12.5%. PAT grew 5.4% YoY to Rs. 38.9 crores, moderated by higher project depreciation. Exports surged 33.8% YoY to Rs. 216.4 crores. By segment, HPPC grew 18%, TSC 26%, and AHN 11% YoY. H1FY27 net debt declined to Rs. 221 crores from Rs. 281 crores in Mar'26, and working capital reduced to 86 days. The board approved leasing land for a greenfield facility in Saudi Arabia.
Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2026.
Financial Result · 18 Oct 2026, 1:24 am
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 18 Oct 2026, 1:04 am
Rossari Biotech Posts Q2 FY27 Results; Approves KSA Greenfield Land Lease Rossari Biotech reported Q2 FY27 consolidated revenue of ₹6,975.60 mn, up 19.0% YoY, with net profit rising 5.5% YoY to ₹389.07 mn. Diluted EPS stood at ₹7.02 versus ₹6.65 in Q2 FY26. For H1 FY27, revenue reached ₹13,947.60 mn and PAT increased to ₹740.02 mn. In a key strategic move, the board approved the leasing of land by wholly owned subsidiary Rossari International Company Limited to establish a greenfield manufacturing facility in Saudi Arabia, with project details and capex pending finalization.
Outcome of Board Meeting held on October 17, 2026.
Outcome · 18 Oct 2026, 12:41 am
Outcome of Board Meeting Held On October 17, 2026
Outcome · 18 Oct 2026, 12:41 am
Rossari Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 6,976 (+19.0% YoY | +0.1% QoQ) ■ EBITDA: 870 (+20.9% YoY | +7.9% QoQ) ■ EBITDA Margin (%): 12.5 (+20 bps YoY | +90 bps QoQ) ■ PAT: 389 (+5.5% YoY | +10.9% QoQ) ■ EPS (INR): 7.02 (+5.6% YoY | +10.9% QoQ)
Intimation of Earnings Conference Call for investor and analyst on Monday, October 19, 2026 at 04:00 P.M. (IST).
Intimation · 19 Oct 2026, 4:00 pm
Rossari Biotech Schedules Q2 & H1 FY27 Earnings Call on October 19, 2026 Rossari Biotech Limited will host its Q2 & H1 FY27 earnings conference call on Monday, 19th Oct'26, at 04:00 PM IST to discuss its financial and operational performance for the period ended 30th Sep'26. The call will be led by key management members, including Executive Chairman Edward Menezes, Managing Director Sunil Chari, and Group CFO Ketan Sablok, and will feature a discussion on results followed by an interactive Q&A session.
Rossari Biotech Limited has informed the Exchange about Board Meeting to be held on 17-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 17 Oct 2026, 5:30 am
Rossari Biotech Ltd has informed NSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2026 ,inter alia, to consider and approve Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026.
Intimation · 17 Oct 2026, 5:30 am
Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 17 Oct 2026, 5:30 am
Rossari Biotech Schedules Board Meeting on 17th Oct'26 to Approve Q2 Results Rossari Biotech Limited announced that its Board of Directors will meet on 17th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities remains closed for designated persons and their immediate relatives from 1st Oct'26 until 48 hours after the declaration of the financial results.
Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Intimation · 16 Sept 2026, 8:38 pm
Rossari Biotech to Attend Anand Rathi Flagship Conference in Mumbai Rossari Biotech Limited announced its participation in the Anand Rathi Annual Flagship Conference G-200 Summit 2026, scheduled for 22nd Sep'26 from 02:00 PM IST onwards in Mumbai. The company will engage in one-on-one and group meetings with investors and analysts. Discussions will strictly focus on publicly available financial information and the earnings presentation submitted on 19th Jul'26, with no unpublished price-sensitive information being shared.
Intimation of Analyst/Institutional Investors Meet/Con. Call/Updates.
Intimation · 11 Sept 2026, 1:38 am
Rossari Biotech Schedules Investor and Analyst Meetings for Sep'26 Rossari Biotech Limited announced its participation in one-on-one and group investor/analyst meetings scheduled for 17th Sep'26 in Mumbai, starting at 10:00 AM IST. Discussions will strictly focus on publicly available financial information and the Earnings Presentation submitted to stock exchanges on 19th Jul'26. The company confirmed that no unpublished price-sensitive information (UPSI) will be shared during these interactions.
Intimation of non-participation in the investors and analysts meet scheduled on Monday, August 10, 2026.
Intimation · 07 Aug 2026, 1:33 am
Rossari Biotech Cancels Participation in Upcoming Investor Conference Rossari Biotech Limited (ROSSARI) has announced its non-participation in the Nirmal Bang Semi-Annual Investor Conference, which was scheduled for 10 Aug'26. The company provided this update via an exchange filing on 06 Aug'26, referencing a prior intimation from 03 Aug'26. No reason for the withdrawal was cited in the notice.
Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Intimation · 04 Aug 2026, 1:26 am
Rossari Biotech Schedules Investor Meetings in Mumbai Rossari Biotech Limited announced its participation in Nirmal Bang's Semi-Annual Investor Conference in Mumbai on 10 Aug'26. The company will conduct one-on-one and group meetings with investors and analysts. Discussions will be based on publicly available information, including the earnings presentation submitted on 19 Jul'26. Rossari confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these interactions. The schedule remains subject to potential changes based on company or investor exigencies.
Intimation of Transcript of Q1 FY 27 for the Earnings Conference Call held on July 20, 2026.
Transcript · 25 Jul 2026, 2:01 am
Scrutinizer''s Report for the 17th Annual General Meeting of the Members of the Company.
Annual General Meeting · 21 Jul 2026, 3:34 am
Outcome of 17th Annual General Meeting of the Members of the Company along with Proceedings, Voting Results and Scrutinizers Report.
Annual General Meeting · 21 Jul 2026, 3:21 am
Audio recording of Earnings Conference Call for Q1 FY 27.
Audio / Video · 21 Jul 2026, 2:55 am
Rossari Biotech Makes Q1 FY27 Earnings Call Recording Available Rossari Biotech announced the audio recording of its Q1 FY27 earnings conference call with analysts and investors is now available. The call was held on 20-Jul'26. Interested parties can access the recording on the company's official website under the 'Investor Call' section. This follows the company's intimation letter dated 14-Jul'26 regarding the event.
Update on Grant of Options.
Others (Uncategorized) · 21 Jul 2026, 2:38 am
Rossari Biotech Corrects ESOP Grant Figures Rossari Biotech issued a clarification on 20 Jul'26, correcting the number of options granted under its Employee Stock Option Plan 2019. The company stated that its previous intimation on 18 Jul'26 inadvertently mentioned 4,000 options. The correct number of options granted by the board is 5,000. All other details from the prior announcement remain unchanged.
Rossari Biotech Limited informed the Exchange regarding Press Release dated July 18, 2026 titled " Rossari Biotech Limited announces Q1 FY 27 results".
Press Release · 19 Jul 2026, 9:58 pm
Rossari Biotech Delivers Highest-Ever Quarterly Revenue in Q1 FY27 Rossari Biotech reported its highest-ever quarterly revenue of Rs. 697.2 crore for Q1 FY27, a 28% YoY increase. Consolidated EBITDA grew 19% YoY to Rs. 80.6 crore, though margins compressed to 11.6% from 12.5%. PAT saw a modest 4% YoY rise to Rs. 35.1 crore. All key segments (HPPC, TSC, AHN) delivered strong YoY growth of 28%, 28%, and 27% respectively. The company also established a 5,000 MTPA greenfield blending facility in Thailand to strengthen its Southeast Asia presence and continued monetizing non-core assets.
Intimation of Q1 FY27- Earnings Presentation.
Investor Presentation · 19 Jul 2026, 9:48 pm
Rossari Biotech Q1 FY27: Record Revenue and EBITDA Driven by Broad-Based Growth Rossari Biotech reported record quarterly revenue and EBITDA for Q1 FY27, driven by strong growth across its business segments. Consolidated revenue from operations grew 28.2% YoY to Rs. 697.2 crore, while EBITDA increased 18.7% YoY to Rs. 80.6 crore. PAT rose 4.5% YoY to Rs. 35.1 crore. The core B2B business (excluding Institutional/B2C) saw robust revenue growth of 32% YoY with a 14% EBITDA margin. HPPC, TSC, and AHN segments grew 28%, 28%, and 27% YoY, respectively, reflecting healthy demand and expanding international presence.
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 18 Jul 2026, 10:32 pm
Rossari Biotech Board Approves Q1FY27 Results and Corporate Actions For Q1FY27 ending 30 Jun'26, consolidated revenue was ₹6,972.0 mn (+28.2% YoY), with PAT at ₹351.0 mn (+4.5% YoY). The Board approved granting 4,000 ESOPs at an exercise price of ₹531 and allotted 2,500 shares. Additionally, the company is undertaking an internal restructuring by transferring its 100% holding in Rossari International to its Singapore subsidiary, Rossari (Singapore) Pte. Ltd., for a consideration of ~₹24 Crores. This move aims to consolidate overseas subsidiaries under a single holding platform and is expected to complete by 31 Mar'27.
Intimation of grant of 4000 options Under Rossari Employee Stock Option Plan - 2019
Others (Uncategorized) · 18 Jul 2026, 10:26 pm
Rossari Biotech Approves Q1FY27 Results and ESOP Grants Rossari Biotech's Board approved Q1FY27 consolidated results and several corporate actions on 18 Jul'26. It granted 4,000 options at an exercise price of Rs. 531 under ESOP 2019 and allotted 2,500 equity shares at Rs. 425. The Board also approved an internal restructuring, transferring its 100% stake in Rossari International Limited to its wholly-owned Singapore subsidiary for ~Rs. 24 Crores. Consolidated PAT for the quarter ended 30 Jun'26 stood at Rs. 351 million on revenue of Rs. 6,972 million.